Literature DB >> 8485114

Substrate delivery as a determinant of hepatic apoB secretion.

A D Sniderman1, K Cianflone.   

Abstract

The evidence that apoB particles secreted by the liver can differ in number and composition has been reviewed. No evidence has yet emerged that changes in apoB100 itself affect the rate of its secretion from the liver. The metabolic role of apoB appears to be the prevention of lipid accumulation within the liver cell: when delivery of lipid to the liver increases, apoB secretion will increase pari passu. This reality in no way detracts from the critical role played by the LDL receptor in determining the number of LDL particles in plasma, nor does it diminish the potential importance of intracellular processes such as 7 alpha-hydroxylase activity to also mediate LDL receptor activity. However, it should be obvious that variation in catabolism by itself cannot explain all that has been observed in physiological and pathological studies. On the contrary, the whole process must be taken into account--the rate at which apoB particles are added to the circulation, the rate at which they are converted to LDL, and the rate at which they are irreversibly removed from plasma--if we are to understand and appreciate this most peculiar and most important of transport systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485114     DOI: 10.1161/01.atv.13.5.629

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  27 in total

1.  Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia.

Authors:  Heiner K Berthold; Jessica Mertens; Julia Birnbaum; Susanne Brämswig; Thomas Sudhop; P Hugh R Barrett; Klaus von Bergmann; Ioanna Gouni-Berthold
Journal:  Lipids       Date:  2010-05-12       Impact factor: 1.880

Review 2.  Hepatic regulation of apolipoprotein B.

Authors:  Rita Kohen Avramoglu; Khosrow Adeli
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

3.  Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure.

Authors:  Jonathan C Jun; Luciano F Drager; Samer S Najjar; Stephen S Gottlieb; Cynthia D Brown; Philip L Smith; Alan R Schwartz; Vsevolod Y Polotsky
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

Review 4.  Role of insulin in hepatic fatty acid partitioning: emerging concepts.

Authors:  V A Zammit
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

5.  Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function.

Authors:  Alison B Kohan; Fei Wang; Xiaoming Li; Suzanne Bradshaw; Qing Yang; Jody L Caldwell; Tera M Bullock; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-29       Impact factor: 4.052

6.  Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet.

Authors:  L C Hudgins; M Hellerstein; C Seidman; R Neese; J Diakun; J Hirsch
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

Review 7.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

8.  Fetal macrosomia related to maternal poorly controlled type 1 diabetes strongly impairs serum lipoprotein concentrations and composition.

Authors:  H Merzouk; M Bouchenak; B Loukidi; S Madani; J Prost; J Belleville
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

9.  Extended-release niacin acutely suppresses postprandial triglyceridemia.

Authors:  M Haris U Usman; Arman Qamar; Ramprasad Gadi; Scott Lilly; Harsh Goel; Jaison Hampson; Megan L Mucksavage; Grace A Nathanson; Daniel J Rader; Richard L Dunbar
Journal:  Am J Med       Date:  2012-07-25       Impact factor: 4.965

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.